4//SEC Filing
ANDO DALE G 4
Accession 0001181431-12-055804
CIK 0001001233other
Filed
Oct 28, 8:00 PM ET
Accepted
Oct 29, 9:53 PM ET
Size
10.5 KB
Accession
0001181431-12-055804
Insider Transaction Report
Form 4
ANDO DALE G
VP, Therapeutic Dev. & CMO
Transactions
- Sale
Common Stock
2012-10-26$5.69/sh−15,000$85,335→ 63,534 total - Exercise/Conversion
Common Stock
2012-10-26$3.61/sh−15,000$54,150→ 78,534 total - Exercise/Conversion
Employee Stock Option (Right to Buy)
2012-10-26−15,000→ 65,800 totalExercise: $3.61Exp: 2014-08-01→ Common Stock (15,000 underlying) - Sale
Common Stock
2012-10-26$5.72/sh−5,000$28,600→ 58,534 total
Footnotes (4)
- [F1]The sales reported in this Form 4 were effected pursuant to the Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2012, amended on September 12, 2012.
- [F2]The price reported in Column 4 is a weighted average price. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.60 to $5.94, inclusive. The reporting person undertakes to provide to Sangamo Biosciences Inc., any security holder of Sangamo Biosciences Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3) to this Form 4.
- [F3]These shares were sold in multiple transactions at prices ranging from $5.58 to $5.9155, inclusive.
- [F4]All shares underlying this option are vested and immediately exercisable.
Documents
Issuer
SANGAMO BIOSCIENCES INC
CIK 0001001233
Entity typeother
IncorporatedDE
Related Parties
1- filerCIK 0001202278
Filing Metadata
- Form type
- 4
- Filed
- Oct 28, 8:00 PM ET
- Accepted
- Oct 29, 9:53 PM ET
- Size
- 10.5 KB